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Emblica officinalis is an ayurvedic herbal plant. The compounds isolated from this plant have good inhibitory effects
against cyclooxygenase-2 (COX-2), among them gallic acid (GA) has the highest inhibitory effect. COX-2 (1.14.99.1)
is an oxidoreductase having a role in prostaglandin biosynthesis, inflammatory responses and in cardiovascular
events. COX-2 has gained special focus on research since past few decades. The sequence and structural studies
reveals Mus musculus COX-2 shares the common conserved sequence and structural pattern with human COX-2.
Molecular modeling and docking analysis with gallic acid and their structural analogues showed that 2-[(2E,4E)-
hexa-2,4-dienyl]-3,4,5-trihydroxybenzoic acid, (3,4,5-trihydroxybenzoyl) 3,4,5-trihydroxybenzoate and 3-hydroxy-4-
sulfooxybenzoic acid are more interactive and binding strongly than gallic acid at active site. Hence these three
compounds should be considered as strong inhibitors for COX-2.
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COX-1 and COX-2 are two distinct isoforms of cyclooxy-
genase, and plays a vital role in conversion of arachidonic
acid to prostaglandins (Lipsky et al. 1998; Vane et al.
1998). Prostaglandins (PGs) are involved in various patho-
physiological processes like inflammatory responses, car-
cinogenesis and in cardiovascular events. COX-2 is not
detectible in most normal tissues, but is induced by proin-
flammatory cytokines, growth factors and carcinogens,
implying a role for COX-2 in both inflammation and con-
trol of cell growth (Subbaramaiah et al. 1996). In inflam-
matory tissues such as rheumatoidal synovium expression
of COX-2 is up regulated and produce prostaglandin pre-
cursors which ultimately converted in to prostaglandins
(Prasit et al. 1999). The recent studies on selective inhi-
bition of COX-2 caused suppression of inflammation and
azoxymethane-induced colon cancer have shown the
importance of COX-2 as a target for anti-inflammatory
and anticancer therapy (Dannhardt and Kiefer, 2001;
Subhashini et al. 2004; Amaravani et al. 2006). Taken to-
gether, these data strongly suggest that suppressing
levels of COX-2 will be an effective strategy for inhibi-
ting inflammation and carcinogenesis.* Correspondence: vrkrishna70@gmail.com
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in any medium, provided the original work is pNon-steroidal anti-inflammatory drugs (NSAIDs) are
effective against inflammation and are observed to in-
hibit PG biosynthesis. NSAIDs inhibit both isoforms of
cyclooxygenases (COX), but they are also associated
with well-known side effects such as gastrointestinal
side effects and renal function suppression (Herschman,
1996). It is known that selective COX-2 inhibitors can
provide anti-inflammatory agents devoid of the undesi-
rable effects associated with classical non-selective
NSAIDs (DeWitt, 1999). As a consequence, increasing
interest has been devoted to the synthesis of inhibitors
of COX-2 by means of modification of well-known
non-selective agents. Apart from selective and non-
selective inhibitors, many natural products have also
been identified as COX-2 inhibitors (Zhang et al. 1999).
As part of the search for natural anti-inflammatory agents
from medicinal plants, Emblica officinalis extracts showed
good medicinal values towards inflammation. Gallic acid
(GA) is a naturally occurring polyhydroxyphenolic com-
pound and an excellent free radical scavenger to inhibit
COX isoforms (Madlener et al. 2007; Pal et al. 2010;
Reddy et al. 2010). Presence of high levels of gallic acid in
Emblica officinalis gives a special status and medicinal
value for treating inflammatory diseases (Ramakrishna
et al. 2011).is an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Figure 1 Secondary structural comparison of human COX-2 and template.
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http://www.springerplus.com/content/1/1/58The present work focuses on the structural analysis of
COX-2, interaction studies with gallic acid at active site
and screening of gallic acid structural analogues. COX-2
active site analysis and molecular docking analysis
enabled us to find better inhibitors as compared to gallic
acid. These interaction studies are very useful to under-
stand the mechanism of COX-2 catalyzed enzymatic
reactions as well as the role of bioactive compounds
interaction with active site residues. The approach is ap-
plicable in engineering 3D structures of enzymatic mo-
dels, and studying interactions of active site residues
with ligands (Nirmal et al. 2011a).Material and methods
Secondary structural analysis
Human COX-2 protein and its structural homologue
protein sequences were retrieved from the NCBI protein
database (www.ncbi.nlm.nih.gov). Pair wise sequence align-
ment of sequences was generated by Clustal W 2.0 (http://
www.ebi.ac.uk/Tools/clustalw2/index.html) and analyzed
to map the secondary structural conservation and varia-
tions. Secondary structural analysis was carried out byFigure 2 Final 3- D model of COX-2 (A) and superimposition with theusing Bioedit 7.0 (Hall, 1999) and Discovery Studio Viewer
(www.accelrys.com).
COX-2 Homology Modeling and optimization
To build the COX-2 homology model, a BLASTp algo-
rithm against Protein Data Bank (PDB) was used to
carry out the sequence homology searches. Crystal struc-
ture of Mus musculus cyclooxygenase 2 (PDB ID: 1PXX)
was taken as a template to build homology model. The
Modeller 9v7 program (Sali and Blundell, 1993) was
employed to generate the 3D models of COX-2. The
model with high score was validated by the Procheck
(Laskowski et al. 1993), VADAR (Willard et al. 2003)
and ProSA (Wiederstein and Sippl, 2007). Further the
model was refined by energy minimization. The energy
minimization was performed using the NAMD package
(Phillips et al. 2005). The optimized model was subjected
to quality assessment with respect to its geometry and
energy and then subjected to molecular docking. Rama-
chandran plot was utilized for geometric evaluation.
ProSA program was employed to evaluate the quality of
model and examine the energy of residue–residue inter-
actions using a distance-based pair potential. The gallictemplate (B).
Figure 3 COX-2 homology model Ramachandran plot.
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http://www.springerplus.com/content/1/1/58acid and its structural analogue molecules downloaded
from Pubchem database of NCBI (Wang et al. 2009),
and converted to 3D structure with VEGA ZZ software
(Pedretti et al. 2004). These molecules were geometric-
ally optimized for further use in docking. C alpha and
back bone atoms root mean square deviation (RMSD) of
template and COX-2 model was calculated by magic fit
program (Guex and Peitsch, 1997).
Model energy minimization and molecular dynamics
3D structure refinement of COX-2 was carried out using
energy minimization and molecular dynamics. It wasFigure 4 Surface representation of active site pocket.performed using Nano Molecular Dynamics (NAMD
2.6). The simulations and energy minimization were car-
ried out in 50,000 step minimization of the designed side
chains and solvent to remove bad contacts. Minimum
switching distance of 8.0 Å and a cut off of 12.0 Å for
Vander Walls interactions was used, pair list of the non-
bonded interactions was recalculated every 20 steps with
a pair list distance of 13.5 Å. The resultant energy mini-
mized protein models were used for the active site iden-
tification and for docking with substrates.
Active site analysis
The substrate accessible pockets and active sites of COX-
2 were identified by computed atlas of surface topog-
raphy of proteins (CASTp) calculation (Dundas et al.
2006) and CCDC GOLD (Jones et al. 1997; Verdonk
et al. 2003). To test the accessibility of the pockets were
tested by docking with randomly selected inhibitor mole-
cules. The identified pockets were analyzed for amino
acid cluster groups based on the solvent exposed active
site atoms and bonding capacity of the polar groups.
Docking analysis and inhibitor screening
Gallic acid and its structural analogues are obtained
from Pubchem database of NCBI and converted into 3D
structures with VEGA ZZ software. The docking was
carried out at the binding sites by CCDC’s GOLD (ge-
netic optimization for ligand docking). One-hundred
genetic algorithm (GA) runs were performed for each
compound, and 10 ligand bumps were allowed in an at-
tempt to account for mutual ligand/target fit. The bind-
ing region for the docking study was defined as a 10 Å
radius sphere centered on the active site. For each of the
GA run a maximum number of 100,000 operations were
performed on a population of 100 individuals with a se-
lection pressure of 1.1. The number of islands was set to
5 with a niche size of 2. The weights of crossover, muta-
tion, and migration were set to 95, 95, and 10 respect-
ively. The scoring function Gold Score implemented in
GOLD was used to rank the docking positions of the
molecules, which were clustered together when differing
by more than 2 Å RMSD (Phogat et al. 2010; Nirmal
et al. 2011b). The best ranking clusters for each of the
molecules were selected. Hydrogen bonds, bond lengths
and close contacts between enzyme active site and li-
gand atoms were analyzed.
Results and discussion
Secondary structural features
Comparative secondary structural analysis of COX-2
with template reveals that the secondary structural ele-
ments were well conserved. The secondary structural
comparison of COX-2 was presented in Figure 1. Se-
condary structure of the COX-2 showing same pattern
Table 1 Properties of COX-2 active site residue
composition and accessible atoms
S.No Residue No. of Hydrogen donors Atoms
1 ALA185 - -
2 PHE186 - -
3 PHE187 - -
4 ALA188 - -
5 GLN189 - -
6 HIS190 - -
7 THR192 1 HG1
8 HIS193 - -
9 GLN194 - -
10 PHE196 - -
11 THR198 - -
12 ASN368 1 2HD2
13 LEU370 - -
14 TYR371 - -
15 HIS372 - -
16 TRP373 1 H
17 HIS374 1 HE2
18 LEU376 - -
19 LEU377 - -
20 VAL433 - -
21 SER437 - -
22 GLN440 1 1HE2
23 TYR490 - -
24 LEU493 - -
25 LEU494 - -
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small stretches of beta sheets (2 to 3 amino acids) but
this can be ignored.
COX-2 model
The COX-2 is a 604 amino acids protein. Crystal struc-
tures of COX-2 from different species have already been
determined and available in PDB. Among them, Mus
musculus cyclooxigenase 2 (PDB ID: 1PXX) showed the
highest sequence identity (87%) with COX-2. Practically,
at this level of sequence identity, it is good enough to
use 1PXX as a template, in order to obtain high quality
alignment for the structure prediction by homology
modeling. COX-2 homology (A) and superimposed pose
with Template (B) was shown in Figure 2. The geometry
of the final model of COX-2 was evaluated with Rama-
chandran’s plot calculations computed with the PRO-
CHECK program. This result revealed 91.8% of the
residues were in the core region, 7.6% residues in the
allowed regions and 0.6% in generously allowed region.
COX-2 Ramachandran plot was depicted in Figure 3.
The PROSA analysis of the model showed maximum
residues to have negative interaction energy with very
few residues displayed positive interaction energy and
the overall interaction energy of the model was −7.69
kcal/mol, which is quite similar to the template Z score.
Cα atoms and back bone atoms RMSD of the model
and template was 0.35 Å. The mean residue volume
and total packing volume of the model are 153.9 Å3
and 92962.6 Å3 respectively. VADAR analysis of the
model showed, the mean helix phi, psi and omega
angles are − 65.1, − 40.4 and −178.3 respectively, which is
promising residue packing when compared to the crystal,
structure information. Hence, the final model which
proved to be well validated in terms of geometry and
energy profiles suggests that the model is good enough
to be an initial point for our next stage of molecular
docking studies.
Active site composition
After the final homology model was built, the possible
ligand-binding site of COX-2 was searched by
CASTp calculation and CCDC GOLD. Non-steroidal
anti-inflammatory drug (NSAID) binding site was selectedFigure 5 Docked conformations of (A) Gallic acid and (B) 2-[(2E,4E)-hexfor docking studies. The volume and area of active site are
5331.2 Å3 and 1651.6 Å2 respectively. The active site ac-
commodate by 25 amino acids i.e., ALA185, PHE186,
PHE187, ALA188, GLN189, HIS190, THR192, HIS193,
GLN194, PHE196, THR198, ASN368, LEU370, TYR371,
HIS372, TRP373, HIS374, LEU376, LEU377, VAL433,
SER437, GLN440, TYR490, LEU493 and LEU494. There
were 5 hydrogen donor groups present in the active site.
COX-2 active site was shown in Figure 4. The comparison
of the overall folding and the structure of active site
between COX-2 and the template protein reveal a higha-2,4-dienyl]-3,4,5-trihydroxybenzoic acid in the active site pocket.
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were depicted in Table 1.
COX-2 interaction analysis with inhibitors
Initial screening of gallic acid structural analogues was
done by CCDC GOLD docking. There were 59 gallicTable 2 Docking statistics
S.No Ligand
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http://www.springerplus.com/content/1/1/58acid, 3,4-dihydroxy-2-sulfooxybenzoic acid, prop-2-enyl
3,4,5-trihydroxybenzoate, 4-hydroxybutyl 3,4,5-trihydroxy-
benzoate, 3-hydroxypropyl 3,4,5-trihydroxybenzoate, bis
(3,4,5-trihydroxyphenyl)methanone and 1-(3,4,5-trihydrox-
yphenyl)pentan-1-one molecules having high affinity at ac-
tive site and binding firmly. Further docking analysis of
the screened inhibitors revealed 2-[(2E,4E)-hexa-2,4-
dienyl]-3,4,5-trihydroxybenzoic acid, (3,4,5-trihydroxy-
benzoyl) 3,4,5-trihydroxybenzoate and 3-hydroxy-4-
sulfooxybenzoic acid are producing high Gold fitness
score which shows high binding affinity at active site.
The docking conformations of COX-2 with screened
inhibitors were shown in Figure 5. The Gold Score of
all interactions reveals that, among all the ligands, 2-
[(2E,4E)-hexa-2,4-dienyl]-3,4,5-trihydroxybenzoic acid
exhibits the highest fitness score of 45.40. COX-2 dock-
ing statistics were depicted in Table 2.
Conclusion
COX-2 plays a prime role in the prostaglandins biosyn-
thesis pathway as it provides prostaglandin H2, which is
precursor for the formation of all other prostaglandins.
Homology model of COX-2 showed 91.8% of the residues
were in the core region, 7.6% residues in the allowed
regions and 0.6% in generously allowed region of Ram-
chandran plot, suggesting the modeled COX-2 structure
was reliable for the docking studies. The active site analysis
showed 25 residues are present at surface accessible region
of COX-2 active site. Top ten ranked gallic acid structural
analogues on docking reveals that the 2-[(2E,4E)-hexa-2,4-
dienyl]-3,4,5-trihydroxybenzoic acid has more affinity at
active site than others. This information has potential
implications to understand the mechanism of COX-2
related enzymatic inhibition reactions, and also applicable
in the prediction of more effective inhibitors and engineer-
ing 3D structures of other enzymes as well.
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